Oxford-AstraZeneca vaccine is cheaper than Pfizer's and Moderna's and doesn't require supercold temperature

There is now a third vaccine that prevents COVID-19 infections. It isn't quite as effective as the other two vaccines but it has advantages that may make it the frontrunner.

Sanjay Mishra, Project Coordinator & Staff Scientist, Vanderbilt University Medical Center, Vanderbilt University • conversation
Nov. 24, 2020 ~9 min

 covid-19  immune-system  pandemic  vaccines  sars-cov-2  antibody  university-of-oxford  astrazeneca  covid-19-vaccines  pfizerbiontech-vaccine  moderna-vaccine  pfizer-vaccine

What monoclonal antibodies are – and why we need them as well as a vaccine

Monoclonal antibodies are synthetic molecules manufactured in the lab. But do we need them if a vaccine is on its way?

Rodney E. Rohde, Professor Clinical Laboratory Science, Texas State University • conversation
Nov. 16, 2020 ~9 min

 covid-19  pandemic  sars-cov-2  remdesivir  viruses  antibody  steroids  monoclonal-antibodies  convalescent-plasma  dexamethasone

Antibody evolution may predict COVID-19 outcomes

For COVID-19, the difference between surviving and not surviving severe disease may be due to the quality, not the quantity, of the patients’ antibody development and response, suggests a new study.

Harvard Gazette • harvard
Nov. 13, 2020 ~3 min

covid-19 health-medicine ragon-institute antibody-evolution igg-antibodies

Achieving COVID-19 herd immunity through infection is dangerous, deadly and might not even work

Some have suggested the US allow healthy people to return to normal life, catch the coronavirus and get the population to herd immunity. The science says this plan is doomed to fail from the start.

Steven Albert, Professor and Chair of Behavioral and Community Health, University of Pittsburgh • conversation
Oct. 28, 2020 ~10 min

covid-19 coronavirus donald-trump vaccines antibodies sars-cov-2 immunity herd-immunity viruses sweden antibody-testing death-rate case-fatality-rate

Cigarette smoke can reprogram cells in your airways, causing COPD to hang on after smoking ends

A new discovery offers hope for ways to treat a debilitating disease that has become a leading cause of death in the US..

Bradley Richmond, Assistant Professor of Medicine, Vanderbilt University • conversation
Oct. 28, 2020 ~8 min

health medicine inflammation smoking tobacco lungs antibodies lung-disease breathing cigarettes copd

COVID-19 causes some patients' immune systems to attack their own bodies, which may contribute to severe illness

Are antibodies that attack a patient's own organs contributing to severe forms of COVID-19? A new study suggests specific antibody tests that may reveal the answer.

Matthew Woodruff, Instructor, Lowance Center for Human Immunology, Emory University • conversation
Oct. 23, 2020 ~8 min

covid-19 immune-system pandemic antibodies sars-cov-2 viruses autoimmune-diseases autoimmune-illness

SARS-CoV-2 immunity lasts for at least 5 months

SARS-CoV-2 antibodies persist in the body for months after infection. "This research… has armed us with the knowledge that lasting immunity is a reality."

Stacy Pigott-Arizona • futurity
Oct. 15, 2020 ~7 min

covid-19 antibodies viruses featured health-and-medicine immune-systems

COVID survivors may have four months of protection

A new study shows that people who survive serious COVID-19 infections have long-lasting immune responses against the virus.

Harvard Gazette • harvard
Oct. 8, 2020 ~4 min

covid-19 health-medicine massachusetts-general-hospital antibodies long-lasting-immune-responses

An autoimmune-like antibody response is linked with severe COVID-19

Patients suffering from severe COVID-19 may be experiencing a rogue antibody response similar to that seen in autoimmune diseases. The findings offer new approaches for COVID-19 therapy.

Matthew Woodruff, Instructor, Lowance Center for Human Immunology, Emory University • conversation
Oct. 8, 2020 ~8 min

 covid-19  immune-system  pandemic  sars-cov-2  viruses  infection  cytokine-storm  antibody  autoimmune-diseases  b-cell

One small part of a human antibody has the potential to work as a drug for both prevention and therapy of COVID-19

Antibodies are great for neutralizing viruses. But they are big and bulky. Antibody engineers are now creating smaller synthetic antibody-like molecules that may be better for fighting COVID-19.

Dimiter Stanchev Dimitrov, Professor of Medicine and Director, Center for Antibody Therapeutics, University of Pittsburgh • conversation
Oct. 1, 2020 ~9 min

 health  medicine  immune-system  pandemic  immunology  sars-cov-2  covid-19-pandemic  ace2  antibody  innovation-and-invention  covid-19-research

Page 1 of 7